DLAT and prostate adenocarcinoma: Contrastingly, the expression of DLAT was shown to be low in nine different malignancies: breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), colon adenocarcinoma/rectum adenocarcinoma (COADREAD), head and neck squamous cell carcinoma (HNSC), pan-kidney cohort (KIPAN), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), prostate adenocarcinoma (PRAD), and thyroid carcinoma (THCA).